Veeva Sys Inc Stock Price, News & Analysis

Veeva Systems' latest Pulse Field Trends Report reveals that targeted pre-launch scientific outreach significantly accelerates treatment adoption. Key findings include:

1. Biopharmas investing in pre-launch scientific activities and prioritizing congresses achieve 40% faster treatment adoption.
2. Early-career experts are four times more likely to start patients on new treatments and more open to digital engagement.
3. Congress activity has the strongest influence on clinical decisions post-approval.
4. Engaging early-career HCPs increases new treatment uptake, with these experts being five times more likely to speak at congresses and 11 times more likely to engage digitally.

The report emphasizes the importance of expanding engagement strategies beyond traditional experts and investing in different types of scientific outreach to drive greater impact and faster treatment adoption.

Veeva Systems (NYSE: VEEV) announced a partnership with Vita Global Sciences to enhance clinical data management through Veeva Vault EDC. This collaboration aims to streamline processes, improve patient and stakeholder experiences, and accelerate study builds. Kelly Forester, director of clinical data management at Vita Global Sciences, highlighted the goal of delivering impactful innovations. Future plans include integrating Veeva Clinical Database (CDB) and Veeva RTSM to further optimize trial data management and patient randomization. Jon Young from Veeva emphasized that these advancements will help Vita Global Sciences achieve faster, more accurate trials.

Veeva Systems (NYSE: VEEV) announced that Hangzhou Tigermed Consulting has chosen Veeva Vault EDC as its foundational technology for electronic data capture (EDC). This adoption is expected to streamline complex data management processes, enabling faster study builds and mid-study amendments without downtime. Tigermed aims to enhance clinical trial management and data quality, benefiting both their clients and the broader industry. The collaboration with Veeva aligns with Tigermed's ongoing investment in new technology to maintain a competitive edge in clinical research. Veeva Vault EDC is part of Veeva's Clinical Platform, widely used by top biopharmaceutical companies and contract research organizations (CROs).

Veeva Systems (NYSE: VEEV) has announced their participation in two upcoming investor conferences. Paul Shawah, EVP of Commercial Strategy, will present at the William Blair 44th Annual Growth Stock Conference in Chicago, IL, on June 5, 2024, at 2:00 p.m. Central Time. He will also present at the Baird 2024 Global Consumer, Technology & Services Conference in New York, NY, on June 6, 2024, at 9:40 a.m. Eastern Time. Both presentations will be webcast live and archived for later viewing on Veeva's investor relations website.

Veeva Systems (NYSE: VEEV) announced its fiscal 2025 first quarter results with total revenues reaching $650.3 million, up 24% year-over-year. Subscription services revenue increased by 29% to $534 million. The company reported a significant rise in operating income, which grew by 152% to $155.2 million, and non-GAAP operating income increased by 66% to $260.9 million. Net income saw an increase of 23% to $161.7 million, with non-GAAP net income rising by 67% to $247 million. Earnings per share (EPS) also grew, with fully diluted net income per share at $0.98 and non-GAAP fully diluted net income per share at $1.50. Veeva highlighted key wins with top biopharmas, progress in CRM and Data Cloud solutions, and provided positive guidance for the upcoming quarters.

Veeva Systems (NYSE: VEEV) unveiled findings from its Veeva Pulse Field Trends Report, highlighting a significant drop in healthcare professional (HCP) access, now at 45% compared to 60% eighteen months ago. The report underscores the effectiveness of a connected engagement model, where sales, marketing, and medical teams coordinate efforts to build more relevant and trusted HCP relationships. This approach helps biopharma companies overcome access barriers, increasing HCP engagement through digital and in-person touchpoints. The findings indicate that HCPs are more selective, often engaging with only three or fewer companies, and that specialties such as internal medicine, oncology, psychiatry, and urology have stricter access limitations. Despite these challenges, coordinated engagement has proven beneficial in extending conversations and improving treatment adoption.

Veeva Systems (NYSE: VEEV) announced that its Veeva MedTech platform has been named 'Best Overall MedTech Software' for the second consecutive year in the MedTech Breakthrough Awards. The award recognizes Veeva MedTech's innovation and excellence in helping medical device and diagnostic companies streamline processes through its unified cloud platform. Veeva MedTech's solutions, including Veeva Vault Clinical, RIM, Quality, Commercial, and Medical, offer comprehensive lifecycle management. Veeva partners with over 125 companies to enhance efficiency, speed, and compliance. This marks Veeva MedTech's third recognition by MedTech Breakthrough, following a win for 'Best Clinical Efficiency Solution' in 2022.

Veeva Systems (NYSE: VEEV) has launched Veeva Vault Basics, a new turnkey solution tailored for biotechs, which includes technology, training, and support with zero implementation and maintenance costs.

This offering allows biotechs to swiftly adopt industry-leading Veeva Vault applications, thereby enhancing efficiency, speed, and compliance. Currently, ten biotechs are using Vault Basics, which equips them with tools to manage growth effectively without additional costs.

The solution includes Vault eTMF Basics, Vault QualityDocs and Training Basics, and Vault Submissions and Submissions Archive Basics, providing a comprehensive suite for clinical trials, GxP document management, and regulatory submissions. Vault Basics is now available in North America, with additional offerings expected in 2025.

Veeva Systems (NYSE: VEEV) will release its fiscal 2025 first-quarter financial results on May 30, 2024, after the market closes. A conference call and webcast will be held at 2:00 p.m. PT (5:00 p.m. ET) on the same day to discuss the results. Prepared remarks will be posted on Veeva's investor relations website before the call. A webcast replay will be available on the website after the event.